Viking Therapeutics VKTX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's investment proceeds?
- Viking Therapeutics (VKTX) reported investment proceeds of $126.63M in Q1 2026.
- How has Viking Therapeutics's investment proceeds changed year-over-year?
- Viking Therapeutics's investment proceeds decreased by 57.2% year-over-year, from $295.86M to $126.63M.
- What is the long-term trend for Viking Therapeutics's investment proceeds?
- Over 4 years (2021 to 2025), Viking Therapeutics's investment proceeds has grown at a 38.6% compound annual growth rate (CAGR), from $205.98M to $759.43M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.